Dr. Skarbnik on the Optimization of CAR T-Cell Therapy Sequencing in MCL

Video

Alan P. Z. Skarbnik, MD, discusses the optimization of treatment sequencing with CAR T-cell therapy in mantle cell lymphoma.

Alan P. Z. Skarbnik, MD, a hematologist/oncologist with Novant Health, discusses the optimization of treatment sequencing with CAR T-cell therapy in mantle cell lymphoma (MCL).

The long-term efficacy with CAR T-cell therapy in MCL is not yet fully understood, says Skarbnik. Additionally, it is unknown whether sequencing CAR T-cell therapy before a BTK inhibitor affects response rate or duration of response in this patient population, Skarbnik says. Retrospective data could inform whether that sequencing strategy is feasible and efficacious, Skarbnik adds.

Currently, CAR T-cell therapy appears to have the most utility after frontline induction therapy in younger patients with MCL who experience early recurrence and have undergone transplant, Skarbnik says. Additionally, the modality is warranted in patients who recur after treatment with BTK inhibitors because few available agents are able to salvage these patients, Skarbnik says. In addition to CAR T-cell therapy, rituximab (Rituxan) plus bendamustine and low-dose cytarabine has demonstrated good response rates in patients with MCL who have relapsed on or are refractory to BTK inhibitors, concludes Skarbnik.

Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
© 2024 MJH Life Sciences

All rights reserved.